Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative ...

today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized ... least squares [LS] mean difference, -1.5 [95% CI, -2.4, -0.5]; P ...

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in ...

or anti–muscle-specific kinase antibody positive (MuSK+). 1 The approval of the FcRn-blocking monoclonal antibody, which works by reducing immunoglobulin G (IgG), was supported by data from the ...

These results provide reassurance to the families of children born to anti-Ro antibody positive mothers. A total of 321 surveys were completed, 91% by parents and 9% by patients themselves.

Shares of iBio, Inc.(IBIO) were in the spotlight on Monday after the company announced positive data from ... human primates shows that the anti-myostatin antibody could provide a weight loss ...

The phase 3 MINT trial included more than 200 adults with anti–acetylcholine receptor antibody–positive (AChR+ ... inebilizumab (mean age, 47.1 years; 66.4% women) and the other 119 received ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...